Peptide Vaccine Therapy in Colorectal Cancer
AbstractColorectal cancer is the third most common cause of cancer-related deaths and the second most prevalent (after breast cancer) in the western world. High metastatic relapse rates and severe side effects associated with the adjuvant treatment have urged oncologists and clinicians to find a novel, less toxic therapeutic strategy. Considering the limited success of the past clinical trials involving peptide vaccine therapy to treat colorectal cancer, it is necessary to revise our knowledge of the immune system and its potential use in tackling cancer. This review presents the efforts of the scientific community in the development of peptide vaccine therapy for colorectal cancer. We review recent clinical trials and the strategies for immunologic monitoring of responses to peptide vaccine therapy. We also discuss the mechanisms underlying the therapy and potential molecular targets in colon cancer. View Full-Text
Scifeed alert for new publicationsNever miss any articles matching your research from any publisher
- Get alerts for new papers matching your research
- Find out the new papers from selected authors
- Updated daily for 49'000+ journals and 6000+ publishers
- Define your Scifeed now
Bartnik, A.; Nirmal, A.J.; Yang, S.-Y. Peptide Vaccine Therapy in Colorectal Cancer. Vaccines 2013, 1, 1-16.
Bartnik A, Nirmal AJ, Yang S-Y. Peptide Vaccine Therapy in Colorectal Cancer. Vaccines. 2013; 1(1):1-16.Chicago/Turabian Style
Bartnik, Aleksandra; Nirmal, Ajit Johnson; Yang, Shi-Yu. 2013. "Peptide Vaccine Therapy in Colorectal Cancer." Vaccines 1, no. 1: 1-16.